|
Market Closed -
Other stock markets
|
After hours 05:27:38 am | |||
| 48.15 USD | +2.47% |
|
48.22 | +0.15% |
| 30/06 | CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell Small Cap Comp Growth Benchmark | CI |
| 30/06 | CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell 2500 Growth Benchmark | CI |
Company Valuation: CRISPR Therapeutics AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,799 | 3,183 | 4,972 | 3,360 | 4,998 | 4,742 | - | - |
| Change | - | -45.12% | 56.24% | -32.44% | 48.76% | -5.11% | - | - |
| Enterprise Value (EV) 1 | 3,420 | 1,367 | 3,277 | 1,456 | 3,022 | 3,274 | 3,740 | 4,114 |
| Change | - | -60.02% | 139.65% | -55.58% | 107.58% | 8.36% | 14.23% | 9.99% |
| P/E | 15.2x | -4.86x | -32.3x | -9.07x | -8.11x | -9.85x | -13.2x | -30.2x |
| PBR | 2.4x | 1.69x | 2.63x | 1.75x | 2.45x | 2.48x | 3.23x | 7.17x |
| PEG | - | 0x | 0.4x | -0x | -0.2x | 0.4x | 0.5x | 0.5x |
| Capitalization / Revenue | 6.34x | 2,657x | 13.4x | 90x | 1,424x | 118x | 29.1x | 7.32x |
| EV / Revenue | 3.74x | 1,141x | 8.83x | 39x | 861x | 81.6x | 23x | 6.35x |
| EV / EBITDA | 8.74x | -2.11x | -16.2x | -3.25x | -4.68x | -6.91x | -8.52x | -6.76x |
| EV / EBIT | 9.16x | -2.03x | -14.7x | -3.12x | -4.55x | -6.08x | -8.22x | -13.2x |
| EV / FCF | 7.48x | -2.57x | -12.1x | -10.1x | -8.74x | -8.35x | -16.3x | -52.5x |
| FCF Yield | 13.4% | -39% | -8.24% | -9.94% | -11.4% | -12% | -6.15% | -1.91% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 4.97 | -8.36 | -1.94 | -4.34 | -6.47 | -4.891 | -3.648 | -1.595 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 915 | 1.198 | 371.2 | 37.31 | 3.51 | 40.11 | 162.8 | 647.5 |
| EBITDA 1 | 391.5 | -649 | -202.7 | -447.3 | -645.1 | -474 | -439 | -608.7 |
| EBIT 1 | 373.5 | -673.2 | -222.5 | -466.6 | -664.6 | -538.1 | -454.8 | -311.5 |
| Net income 1 | 377.7 | -650.2 | -153.6 | -366.3 | -581.6 | -487.6 | -375.9 | -159.8 |
| Net Debt 1 | -2,379 | -1,815 | -1,696 | -1,904 | -1,976 | -1,468 | -1,002 | -628.3 |
| Reference price 2 | 75.78 | 40.65 | 62.60 | 39.36 | 52.44 | 48.15 | 48.15 | 48.15 |
| Nbr of stocks (in thousands) | 76,527 | 78,294 | 79,432 | 85,353 | 95,300 | 98,484 | - | - |
| Announcement Date | 15/02/22 | 21/02/23 | 21/02/24 | 11/02/25 | 12/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.61x | 78.79x | -6.67x | -.--% | 462.78Cr | |
| 34.12x | 5.98x | 18.49x | 0.96% | 4.87TCr | |
| -22.64x | 331.03x | -20.73x | -.--% | 3.84TCr | |
| 46.78x | 4.7x | 30.17x | -.--% | 3.45TCr | |
| 24.81x | 2.76x | 11.93x | -.--% | 3.4TCr | |
| 26.65x | 7.82x | 19.63x | 0.43% | 2.68TCr | |
| 31.17x | 5.02x | 22.84x | -.--% | 1.51TCr | |
| 24.35x | 2.08x | 9.15x | 1.08% | 1.42TCr | |
| 23.49x | 1.88x | 11.36x | -.--% | 1.27TCr | |
| Average | 19.90x | 48.89x | 10.69x | 0.27% | 2.54TCr | |
| Weighted average by Cap. | 21.99x | 60.90x | 11.64x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CRSP Stock
- Valuation CRISPR Therapeutics AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition